Literature DB >> 28431200

The utility of flow cytometry in differentiating NK/T cell lymphoma from indolent and reactive NK cell proliferations.

Sanjay de Mel1, Jenny Bei Li2, Muhammad Bilal Abid1, Tiffany Tang3, Hui Ming Tay4, Wen Chang Ting5, Li Mei Poon1, Tae Hoon Chung6, Benjamin Mow5, Allison Tso7, Kiat Hoe Ong7, Wee Joo Chng1,6, Te Chih Liu2.   

Abstract

BACKGROUND: The WHO defines three categories of NK cell malignancies; extra nodal NK/T cell lymphoma (NKTCL), aggressive NK cell leukemia, and the provisional entity chronic lymphoproliferative disorder of NK cells (CLPD-NK). Although the flow cytometric (FC) phenotype of CLPD-NK has been described, studies on FC phenotype of NKTCL are limited. To the best of our knowledge ours is the first study to compare the phenotype of NKTCL, CLPD-NK, reactive NK lymphocytosis (RNKL), and normal NK cells using eight color (8C) FC.
METHODS: Specimens analyzed using the Euroflow8C NK Lymphoproliferative Disorder (NKLPD) panel between 2011 and 2014 were identified from our database. All samples were analyzed on the FACSCantoII cytometer. NK cells were identified as CD45+, smCD3-, CD19-, CD56+ and normal T-cells served as internal controls.
RESULTS: The majority of NKTCL were CD56 bright, CD16 dim, CD57-, and CD94+. CLPD-NK and RNKL were predominantly CD56+ or dim with positive expression of CD16 and CD57 and weak CD94 expression. Antigen based statistical analyses showed robust division of samples along the NKTCL/normal CD56 bright NK cell and CLPD-NK/RNKL/normal CD56 positive NK cell groups.
CONCLUSIONS: It was concluded that FC can reliably distinguish NKTCL from CLPD-NK, normal NK cells of CD56+ phenotype, and RNKL. It was proposed that the typical phenotype for NKTCL is: CD56 bright, CD16 dim with positive CD2, CD7, CD94, HLADR, CD25, CD26, and absent CD57. This resembles the phenotype of the CD56 bright immunoregulatory subset of NK cells which we therefore hypothesize is the cell of origin of NKTCL.
© 2017 International Clinical Cytometry Society. © 2017 International Clinical Cytometry Society.

Entities:  

Keywords:  eight color; flow cytometry; natural killer/T cell

Mesh:

Substances:

Year:  2017        PMID: 28431200     DOI: 10.1002/cyto.b.21529

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  4 in total

1.  Comprehensive Analysis and Summary of the Value of Immunophenotypes of Mature NK Cell Tumors for Differential Diagnosis, Treatment, and Prognosis.

Authors:  Qiyao Pu; Xueyan Cao; Yuke Liu; Dongyao Yan; Ran Tan; Jiwei Li; Baohong Yue
Journal:  Front Immunol       Date:  2022-06-24       Impact factor: 8.786

Review 2.  Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders.

Authors:  Susan Swee-Shan Hue; Siok-Bian Ng; Shi Wang; Soo-Yong Tan
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

3.  Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.

Authors:  Cédric Pastoret; Fabienne Desmots; Gaëlle Drillet; Simon Le Gallou; Marie-Laure Boulland; Alexia Thannberger; Anne-Violaine Doncker; Véronique Salaun; Gandhi Laurent Damaj; Richard Veyrat-Masson; Olivier Tournilhac; Aline Moignet; Céline Pangault; Mikaël Roussel; Thierry Fest; Thierry Lamy
Journal:  Blood       Date:  2021-06-10       Impact factor: 25.476

4.  Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkin's Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India.

Authors:  Prashant R Tembhare; Gaurav Chatterjee; Anumeha Chaturvedi; Niharika Dasgupta; Twinkle Khanka; Shefali Verma; Sitaram G Ghogale; Nilesh Deshpande; Karishma Girase; Manju Sengar; Bhausaheb Bagal; Hasmukh Jain; Dhanalaxmi Shetty; Sweta Rajpal; Nikhil Patkar; Tushar Agrawal; Sridhar Epari; Tanuja Shet; Papagudi G Subramanian; Sumeet Gujral
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.